Sectoral Asset Management Inc bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 34,000 shares of the pharmaceutical company’s stock, valued at approximately $5,169,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Daiwa Securities Group Inc. increased its position in shares of Vertex Pharmaceuticals by 3.2% during the second quarter. Daiwa Securities Group Inc. now owns 7,170 shares of the pharmaceutical company’s stock worth $924,000 after acquiring an additional 220 shares during the period. Global X Management Co. LLC increased its holdings in Vertex Pharmaceuticals by 61.6% in the second quarter. Global X Management Co. LLC now owns 4,441 shares of the pharmaceutical company’s stock valued at $572,000 after buying an additional 1,693 shares during the last quarter. Cigna Investments Inc. New increased its holdings in Vertex Pharmaceuticals by 4.9% in the second quarter. Cigna Investments Inc. New now owns 10,762 shares of the pharmaceutical company’s stock valued at $1,387,000 after buying an additional 504 shares during the last quarter. Wetherby Asset Management Inc. increased its holdings in Vertex Pharmaceuticals by 6.1% in the second quarter. Wetherby Asset Management Inc. now owns 3,378 shares of the pharmaceutical company’s stock valued at $435,000 after buying an additional 193 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in Vertex Pharmaceuticals by 20.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 888,859 shares of the pharmaceutical company’s stock valued at $114,548,000 after buying an additional 150,310 shares during the last quarter. 93.33% of the stock is currently owned by institutional investors.

In related news, CMO Jeffrey Chodakewitz sold 3,437 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Stuart A. Arbuckle sold 221 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $147.29, for a total transaction of $32,551.09. The disclosure for this sale can be found here. Insiders have sold 218,519 shares of company stock valued at $31,819,910 over the last three months. 1.80% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Incorporated (VRTX) opened at $138.78 on Friday. The stock has a market cap of $35,100.00, a PE ratio of 230.60, a P/E/G ratio of 3.31 and a beta of 1.57. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.49. The firm had revenue of $578.20 million during the quarter, compared to analysts’ expectations of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The firm’s revenue for the quarter was up 39.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.16 earnings per share. analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.

Several equities analysts recently commented on VRTX shares. Maxim Group reissued a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Royal Bank Of Canada started coverage on Vertex Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $175.00 target price on the stock. Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 target price on the stock in a report on Tuesday, September 26th. DA Davidson started coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They issued a “buy” rating and a $200.00 target price on the stock. Finally, Vetr lowered Vertex Pharmaceuticals to a “sell” rating in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have issued a buy rating to the stock. Vertex Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $173.15.

COPYRIGHT VIOLATION WARNING: “Sectoral Asset Management Inc Buys New Stake in Vertex Pharmaceuticals Incorporated (VRTX)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/08/sectoral-asset-management-inc-buys-new-stake-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.